Using a transcranial magnetic stimulation approach might make it easier to distinguish Alzheimer's disease from frontotemporal dementia.
Neuroimaging and if necessary, genetic testing, can help to confirm an FTD diagnosis.
Eating abnormalities in frontotemporal dementia result from a network of brain regions, rather than 1or 2 specific structures.
Addressing proteasome dysfunction may help prevent accumulation of the toxic protein.
A gene mutation behind a large amount of ALS and FTD cases may disrupt nuclear transport, destroying neurons.
The mouse model will allow researchers to effectively test therapeutic compounds.
The results support the "cognitive reserve" theory that greater mental activity promotes brain connectivity.
C9orf72 hypermethylation helps protect the brain against damage in ALS and frontotemporal degeneration.
Alzheimer's patients had 1.4 times higher concentrations of IAPP than non-Alzheimer's patients in temporal cortex.
The highest dose of intranasal oxytocin seemed to produce the best response.
Neurology Advisor Articles
- Coffee Consumption May Decrease Stroke Risk
- Prochlorperazine More Effective Than Ketamine for Headache Relief in the Emergency Department
- CTE Confirmed With Antemortem PET Imaging, Autopsy in Professional Football Player
- Intranasal Sumatriptan More Effectively Reduces Migraine-Associated Nausea
- Neuropsychiatric Conditions Common in Relatives of Patients With Amyotrophic Lateral Sclerosis
- Treating Cluster Headache: Weighing Current Therapies
- Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly
- NBT System Gets FDA Clearance for Depression Treatment
- Better Migraine Pain Relief With IV Non-Opioid Combination vs IV Hydromorphone
- FDA Approves Myasthenia Gravis Treatment
- Reports of Agranulocytosis Prompt Monitoring for Investigational Parkinson's Drug
- Nusinersen Improves Motor Function, Survival in Infants With Spinal Muscular Atrophy
- Noninvasive Brain Stimulation System Approved for Depression
- Hypertension Guidelines Updated by AHA/ACA
- Bone Mineral Density Associated With Intracranial Aneurysm Presence, Size